(HRMY) Harmony Biosciences Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4131971040

Wakix, Pitolisant, Orexin-Agonist, MCHR1-Antagonist, ZYN-002

Stock: Pharmaceuticals
Age 5.4y

MCap 2,068m
Avg Vol 509K (19.1M USD)

Beta 0.543
Volatility 44.95%

EPS (Earnings per Share)

EPS CAGR: 32.12%
EPS Trend: 32.2%

Last SUE: 1.91
Qual. Beats: 2

Revenue

Rev. CAGR: 29.35%
Rev. Trend: 96.5%

Last SUE: 3.84
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	45.0%
Value at Risk 5%th	65.3%
Relative Tail Risk	-11.65%

Reward TTM
Sharpe Ratio	0.03
Alpha	-14.77
CAGR/Max DD	-0.15

Character TTM
Hurst Exponent	0.603
Beta	0.543
Beta Downside	0.383

Drawdowns 3y
Max DD	61.25%
Mean DD	31.71%
Median DD	31.98%

Description: HRMY Harmony Biosciences Holdings January 13, 2026

Harmony Biosciences Holdings (NASDAQ:HRMY) is a commercial-stage biotech that targets rare and neurological disorders in the U.S., leveraging a pipeline centered on orexin-based and melanin-concentrating-hormone mechanisms.

Its only FDA-approved product, WAKIX (pitolisant), treats excessive daytime sleepiness in adult narcolepsy and generated ≈ $45 million in 2023 net sales, representing the bulk of HRMY’s revenue. The company is expanding pitolisant into new indications: Phase 3 for Prader-Willi Syndrome, Phase 2 for Myotonic Dystrophy (DM1), and early-stage Phase 1 programs for a gastro-resistant and high-dose formulation. Additional pipeline assets include BP1.15205 (orexin-2 agonist), HBS-102 (MCHR1 antagonist), ZYN-002 (Phase 3 for Fragile X and 22q-Deletion syndromes), EPX-100 (serotonin 5-HT2 agonist for Dravet and Lennox-Gastaut), and EPX-200 (lorcaserin liquid for DEE).

Key financial signals as of Q2 2024: cash and equivalents of ≈ $190 million, a runway extending into 2025, and a net loss of $68 million YoY, reflecting heavy R&D spend. The rare-disease neurology market is projected to grow at ~6% CAGR through 2030, driven by unmet needs and premium pricing, which underpins HRMY’s revenue upside if its pipeline clears regulatory milestones.

For a deeper, data-driven look at HRMY’s valuation and comparable peers, ValueRay’s analyst notes provide a concise, decision-ready overview.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income: 185.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.25 > 0.02 and ΔFCF/TA 0.85 > 1.0
NWC/Revenue: 74.51% < 20% (prev 52.96%; Δ 21.55% < -1%)
CFO/TA 0.25 > 3% & CFO 297.6m > Net Income 185.7m
Net Debt (-477.3m) to EBITDA (266.0m): -1.79 < 3
Current Ratio: 3.75 > 1.5 & < 3
Outstanding Shares: last quarter (58.7m) vs 12m ago 1.06% < -2%
Gross Margin: 77.70% > 18% (prev 0.79%; Δ 7691 % > 0.5%)
Asset Turnover: 77.32% > 50% (prev 73.47%; Δ 3.86% > 0%)
Interest Coverage Ratio: 15.81 > 6 (EBITDA TTM 266.0m / Interest Expense TTM 15.3m)

Altman Z'' 5.63

A: 0.51 (Total Current Assets 838.8m - Total Current Liabilities 223.4m) / Total Assets 1.21b
B: 0.11 (Retained Earnings 138.4m / Total Assets 1.21b)
C: 0.23 (EBIT TTM 242.2m / Avg Total Assets 1.07b)
D: 0.37 (Book Value of Equity 138.8m / Total Liabilities 373.1m)
Altman-Z'' Score: 5.63 = AAA

Beneish M -3.12

DSRI: 1.02 (Receivables 100.7m/81.5m, Revenue 825.9m/681.9m)
GMI: 1.01 (GM 77.70% / 78.65%)
AQI: 0.70 (AQ_t 0.30 / AQ_t-1 0.43)
SGI: 1.21 (Revenue 825.9m / 681.9m)
TATA: -0.09 (NI 185.7m - CFO 297.6m) / TA 1.21b)
Beneish M-Score: -3.12 (Cap -4..+1) = AA

ValueRay F-Score (Strict, 0-100) 92.90

1. Piotroski: 7.0pt
2. FCF Yield: 18.97%
3. FCF Margin: 35.95%
4. Debt/Equity: 0.20
5. Debt/Ebitda: -1.79
6. ROIC - WACC: 12.39%
7. RoE: 24.86%
8. Revenue Trend: 96.54%
9. EPS Trend: 32.24%

What is the price of HRMY shares?

As of January 26, 2026, the stock is trading at USD 36.82 with a total of 340,732 shares traded.
Over the past week, the price has changed by +2.53%, over one month by -3.44%, over three months by +22.28% and over the past year by -3.74%.

Is HRMY a buy, sell or hold?

Harmony Biosciences Holdings has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy HRMY.

Strong Buy: 5
Buy: 3
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HRMY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	46.5	26.2%
Analysts Target Price	46.5	26.2%
ValueRay Target Price	39.5	7.3%

HRMY Fundamental Data Overview January 22, 2026

P/E Trailing = 11.3281
P/E Forward = 8.0645
P/S = 2.5041
P/B = 2.4766
Revenue TTM = 825.9m USD
EBIT TTM = 242.2m USD
EBITDA TTM = 266.0m USD
Long Term Debt = 148.5m USD (from longTermDebt, last quarter)
Short Term Debt = 20.8m USD (from shortTermDebt, last quarter)
Debt = 169.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -477.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.57b USD (2.07b + Debt 169.7m - CCE 672.6m)
Interest Coverage Ratio = 15.81 (Ebit TTM 242.2m / Interest Expense TTM 15.3m)
EV/FCF = 5.27x (Enterprise Value 1.57b / FCF TTM 296.9m)
FCF Yield = 18.97% (FCF TTM 296.9m / Enterprise Value 1.57b)
FCF Margin = 35.95% (FCF TTM 296.9m / Revenue TTM 825.9m)
Net Margin = 22.48% (Net Income TTM 185.7m / Revenue TTM 825.9m)
Gross Margin = 77.70% ((Revenue TTM 825.9m - Cost of Revenue TTM 184.2m) / Revenue TTM)
Gross Margin QoQ = 75.09% (prev 80.97%)
Tobins Q-Ratio = 1.30 (Enterprise Value 1.57b / Total Assets 1.21b)
Interest Expense / Debt = 2.13% (Interest Expense 3.62m / Debt 169.7m)
Taxrate = 24.63% (16.6m / 67.5m)
NOPAT = 182.5m (EBIT 242.2m * (1 - 24.63%))
Current Ratio = 3.75 (Total Current Assets 838.8m / Total Current Liabilities 223.4m)
Debt / Equity = 0.20 (Debt 169.7m / totalStockholderEquity, last quarter 835.1m)
Debt / EBITDA = -1.79 (Net Debt -477.3m / EBITDA 266.0m)
Debt / FCF = -1.61 (Net Debt -477.3m / FCF TTM 296.9m)
Total Stockholder Equity = 747.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 17.38% (Net Income 185.7m / Total Assets 1.21b)
RoE = 24.86% (Net Income TTM 185.7m / Total Stockholder Equity 747.0m)
RoCE = 27.04% (EBIT 242.2m / Capital Employed (Equity 747.0m + L.T.Debt 148.5m))
RoIC = 19.82% (NOPAT 182.5m / Invested Capital 920.9m)
WACC = 7.43% (E(2.07b)/V(2.24b) * Re(7.91%) + D(169.7m)/V(2.24b) * Rd(2.13%) * (1-Tc(0.25)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.12%
[DCF Debug] Terminal Value 83.13% ; FCFF base≈266.2m ; Y1≈328.4m ; Y5≈559.3m
Fair Price DCF = 193.6 (EV 10.67b - Net Debt -477.3m = Equity 11.15b / Shares 57.6m; r=7.43% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 32.24 | EPS CAGR: 32.12% | SUE: 1.91 | # QB: 2
Revenue Correlation: 96.54 | Revenue CAGR: 29.35% | SUE: 3.84 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.13 | Chg30d=+0.107 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=5.61 | Chg30d=-0.010 | Revisions Net=-1 | Growth EPS=+38.6% | Growth Revenue=+16.3%

Additional Sources for HRMY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle